Showing 1081-1090 of 18563 results for "".
Reframing Sjögren’s Syndrome: Insights from a Comprehensive Review
https://reachmd.com/programs/living-rheum/reframing-sjogrens-syndrome-insights-from-a-comprehensive-review/36335/Anticipated Impacts from the COVID-19 Research Database
https://reachmd.com/programs/covid-19-frontlines/anticipated-impacts-from-the-covid-19-research-database/11515/What might we soon learn about the global COVID-19 pandemic?Responding to COVID-19 in Community Practices: A Dermatologist’s Perspective
https://reachmd.com/programs/covid-19-frontlines/responding-to-covid-19-in-community-practices-a-dermatologists-perspective/11362/In order to help alleviate pressure from hospitals experiencing a high influx of patients due to COVID-19, this doctor decided to keep his doors open.Assessing the Correlation Between Perianal Fistula Healing & Trough Levels of Infliximab in Children with IBD
https://reachmd.com/programs/Audioabstracts/assessing-the-correlation-between-perianal-fistula-healing-and-trough-levels-of-infliximab/10836/Some studies have found that IFX levels matter when treating fistulizing perianal Crohn’s Disease in adults, but is it the same case for children?Increase Engagement through Transparency in Your Practice
https://reachmd.com/programs/healthcares-prescription-web-social-marketing/increase-engagement-through-transparency-in-your-practice/10174/Patients want to know WHO—not necessarily WHAT—you are, and being transparent on a personal and business level is key to bridging that gap.The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
https://reachmd.com/programs/cme/the-impact-of-first-line-treatment-on-subsequent-treatment-options-for-metastatic-escc/33031/Explore emerging data, guideline recommendations, and AE management for first-line anti-PD-1 and chemotherapy regimens in metastatic ESCC.The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
https://reachmd.com/programs/cme/the-importance-of-pd-l1-testing-shaping-the-future-of-treatment-in-escc/29791/Explore emerging data, guideline recommendations, and AE management for first-line anti-PD-1 and chemotherapy regimens in metastatic ESCC.Harnessing the Immune Power: A Uniquely Designed PD-1 Inhibitor for Esophageal Cancer
https://reachmd.com/programs/project-oncology/harnessing-the-immune-power-a-uniquely-designed-pd-1-inhibitor-for-esophageal-cancer/35512/Esophageal cancer is the tenth most common cancer worldwide and the sixth most prevalent cause of death due to cancer, which is why having additional treatment options for this disease is crucial.1 One available option, tislelizumab plus platinum-based chemotherapy, was recently approved by the FDAEnhancing Lupus Nephritis Outcomes: The Potential Impact of Lower Glucocorticoid Doses
https://reachmd.com/programs/living-rheum/enhancing-lupus-nephritis-outcomes-the-potential-impact-of-lower-glucocorticoid-doses/30075/Read about recent findings on the efficacy and safety of low-dose glucocorticoids in patients with lupus nephritis.PCSK9 Inhibitors and Statins: Meta-Analysis Highlights Benefit of Combination Therapy
https://reachmd.com/programs/heart-matters/pcsk9-inhibitors-and-statins-meta-analysis-highlights-benefit-of-combination-therapy/37594/